Your web browser is out of date! We recommend you update your browser to receive the best possible browsing experience.
Download your Brochure
Reserve your place

An Unrivalled Speaker Line-up

See a participant from your company? This means your qualified for a company discounted rate due to your involvement - get in touch for the full information: Jmackintosh@eyeforpharma.com  

Rob Scott MD

Rob Scott MD

Chief Medical Officer, VP Global Development
Abbvie

Read more

Dr Rob Scott is Zimbabwean born and studied medicine at the University of Cape Town. For thirty years Rob has held leadership positions in global Pharma, starting with J&J in South Africa. As the Global Head of CV and Metabolic at Pfizer he was responsible for what was then the world’s largest pharmaceutical product and the largest cardiovascular product – Lipitor and Norvasc. As Executive Vice President of R&D at AtheroGenics in Atlanta Georgia, he designed and implemented the first large cardiovascular outcomes study to be wholly performed by a small biotech. As Chief Medical Officer and Head of Development of Cerenis Therapeutics in Toulouse, France, Rob advanced the science of synthetic HDL. At Amgen, Rob ran the Cardiovascular, Metabolic, Nephrology, Bone, Inflammation and Neuroscience Therapeutic Areas. He also created the Development Design Center, a Center of Excellence focused on using predictive analytics for designing and implementing clinical trials. Rob is currently the Chief Medical Officer and Head of Development at Abbvie. In this role, he is a board member of Transcelerate and a member of the PhRMA Biomedical Advisory Committee. Rob was a member of the FDA Cardiac and Renal Drug Advisory Committee from 2012 to 2016 and also served on the Endocrine and Metabolic Advisory Committee. Rob has been involved with every therapeutic area and mode of drug delivery as well as both small molecules and biologics. He invented and developed the first drug combination to simultaneously treat two different disease states - Caduet.

Sotirios Stergiopoulos

Sotirios Stergiopoulos

CMO, Senior Vice President and Head of Global Medical Affairs
Ipsen

Read more

Dr. Sotirios Stergiopoulos is Chief Medical Officer, Senior Vice President and Head of Global Medical Affairs and a member of the R&D Leadership team at Ipsen BioScience. Sotirios has an extensive experience in directing medical affairs worldwide strategies and plans and a solid expertise in Oncology drug development.

Dr. Stergiopoulos earned his M.D at the University of Medical Sciences of Poznan, Poland. He completed his residency in Internal Medicine at the Albert Einstein College of Medicine (NY), a clinical and research fellowship in Medical Genetics at Harvard Medical School and a research fellowship at National Institutes of Health where he had received an Intramural Research Training Award.

Dr. Stergiopoulos is currently an Attending Physician in the Department of Internal Medicine at Jacobi Medical Center, Albert Einstein College of Medicine (NY). He has been elected as President of the Board of Governors of the Accreditation Council of Medical Affairs and he holds a Masters in Biotechnology Enterprise and Entrepreneurship (MBEE) from The Johns Hopkins University (Baltimore, MD). Sotirios is a Fellow of the New York Academy of Medicine as well as the Royal Society of Medicine (UK). He also is a Member of the American Association of Cancer Research, American Society of Clinical Oncology, and sits on multiple Boards.

Zhen Su

Zhen Su

Chief Medical Officer, North America
EMD Serono

Read more

Dr. Zhen Su, Senior Vice President and Chief Medical Officer of North America for EMD Serono and Head of Global Medical Affairs Oncology (a.i.), heads the North American Medical Affairs organization as well as the medical strategy development and global medical team for the Oncology Franchise.

A physician executive with more than 20 years of experience, Dr. Su has strong clinical expertise in oncology, immuno-oncology and urology. He has held positions in academic and pharmaceutical medicine, including general management, clinical development, medical affairs and business development. Prior to EMD Serono, Dr. Su served in numerous leadership positions at Sanofi and GSK. Before joining industry, Dr. Su held several academic positions, including faculty roles at Duke University and University of Florida.

He has deep ties to the oncology community, having worked with leading oncologists at organizations globally. Dr. Su earned his MD degree from the Technical University of Dresden, Germany and completed his MBA training at the University of Toronto, Canada.

Sandy Leonard

Sandy Leonard

Vice President of Medical Evidence & Observational Research
AstraZeneca

Read more

More information coming soon...

Pol Vandenbroucke

Pol Vandenbroucke

Vice President, Medical Strategy
Pfizer

Read more

Vice President, Medical Strategy, Pfizer Inc., in charge of Global Patient Affairs, the Centers of Excellence for Pediatrics, Diversity in Clinical Trials and Healthy Aging, and the External Bioethics Advisory Panel.

Member of the Board of BIO Ventures for Global Health, and of the American Federation for Aging Research; Member of the Advisory Board of the Steve Biko Centre for Bioethics, University of the Witwatersrand, Johannesburg, South Africa, and of the Keck Graduate Institute, Claremont, CA; Fellow of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Medicine of the United Kingdom and member of its Fellowship and Awards Committee; Module Coordinator Medical Affairs in Medicines Development, IFAPP Academy and King’s College London.

Dr. Vandenbroucke’ s career has been dedicated to Clinical Development, Medical Affairs and Marketing and has included stints in the U.S., Europe, Asia, and Latin America. Before his current position, he was responsible for Medical Affairs of Pfizer’s Essential Health portfolio in North America and he previously also led Clinical Development of all Pfizer compounds in Asia, Central and Eastern Europe, Latin America, and Africa-Middle East and of Pfizer’s Established Products globally. He was also responsible for developing compounds specifically for diseases of the developing world, such as malaria and river blindness.

Prior appointments include Vice President, Medical and Regulatory Affairs, Canada/Latin America/Africa-Middle East, Senior Vice President, Medical Division Pfizer Japan, based in Tokyo, Director of Medical Operations, Asia and Australia/NZ for Pfizer, based in Hong Kong, and Medical Director, Lipitor based in New York, responsible for the international clinical development program of Lipitor.

Before joining Pfizer, Dr. Vandenbroucke was Medical Director, Sterling-Winthrop International; Cardiovascular and CNS Disease Brand Manager at Novartis Mexico, and Brand Assistant at Procter & Gamble Mexico.

He holds a Medical Degree from the Catholic University of Louvain (Belgium), an MBA degree from the Instituto Tecnológico Autónomo de México (ITAM), and an MSc (First Honors) from Hibernia College (Ireland). He is a member of the Pfizer Latino PCC Leadership Team. He is fluent in Dutch, Spanish, English, French, German and basic Japanese.

Scott Williams

Scott Williams

Vice President, Head of Global Patient Advocacy and Strategic Relationships
EMD Serono

Read more

Scott leads our patient advocacy and engagement team as Vice President, Head of Global Patient Advocacy and Strategic Relationships. Prior to joining EMD Serono, Scott held leadership positions at the American Cancer Society Cancer Action Network and Men’s Health Network.

Prior to his patient advocacy experience, Scott held positions in external relations at Sanofi Pasteur and was an analyst at PharmaStrat, a managed care market research company. Scott holds a M.P.A., Executive Leadership from the American University in Washington, D.C., and earned a B.A. cum laude in Political Science from Moravian College in Bethlehem, Pennsylvania. He is based in Washington, DC.

Vivian Herrera

Vivian Herrera

Executive Director, Head of HEOR Payer Strategy
Novartis

Read more

Vivian Herrera is Executive Director and Head of the Immunology & Dermatology, Migraine and HE&OR Payer Strategy Team, within the Department of Health Economics and Outcomes Research at Novartis Pharmaceuticals Corporation.

Vivian completed her Dental degree at Colegio Odontologico Colombiano where she practiced for 2 years. She furthered her education earning a dual masters degree at Columbia University in Public Health and International Affairs. She worked for 11 years on the payer side at Medco currently known as Express scripts in the Advanced Clinical and Science Research team. In her role there she worked on various retrospective and prospective studies in support of various corporate strategic initiatives. Her work was instrumental in identifying gaps and improving the diabetes and depression health programs. E-prescribing and physician detailing were successful initiatives with the help of Vivian’s predictive and regression models on patient and physician behavior. In addition, she was key in the renewal of one of the company’s largest clients by successfully completing a real world program evaluation where she earned Medco’s President Award. More recently she moved to the pharmaceutical industry working for Sanofi in the Global Evidence and Value Development team where she managed the analytic team for Rare diseases and Multiple Sclerosis. She has multiple publications and presentations on Medicare, Diabetes, Cardiovascular, Immunology and Dermatology and Neuroscience therapeutic areas.

Chris Keenan

Chris Keenan

Head, Worldwide Medical Customer Engagement, Medical Capabilities
BMS

Read more

A senior business leader with solid record of leading top performing business units and producing results that have positive impact on the bottom line and customer experience. Diverse worldwide management and operations expertise within financial services, insurance and pharmaceutical sectors. He is a sought-after presenter on topics such as striving for operational excellence, customer engagement and the power of unified data and analytics. Mr. Keenan has been honored by the Philadelphia Direct Marketing Association (PDMA) and the Canadian Direct Marketing Associations (CDMA) for his marketing and operational excellence along with numerous Bristol-Myers Squibb recognitions.

Juan Ochoa

Juan Ochoa

Chief Medical Officer, US
Nestlé

Read more

Dr. Juan Ochoa completed his first residency training in general Surgery with a focus on trauma in Colombia in 1988. He then came to the US to pursue his interests in basic research and was the first to demonstrate that excessive nitric oxide production in humans could explain the hemodynamic instability of sepsis. He began a second residency position at the general surgery program at the University of Pittsburgh in 1991.

In 1996, Dr. Ochoa completed his training and a fellowship in Multidisciplinary Critical Care holding a full time clinical practice in surgery and critical while also obtaining support from the National Institutes of health to continue his independent research on nitric oxide production in trauma and surgery patients. Upon returning to the University of Pittsburgh, Dr. Ochoa became Professor of Surgery and Critical Care and associate director for trauma services at UPMC. During his tenure at the University of Pittsburgh, his laboratory discovered the presence of cells that specialized in destroying the amino acid arginine, explaining why this nutrient is conditionally essential requiring replenishment in patients undergoing surgery or after trauma. In 2008, Ms. Jean Marx in SCIENCE (the journal) interviewed him about the discovery of arginine destruction by myeloid cells. His work has been essential at defining arginine deficiency as a cause of immune dysfunction in several illnesses including surgery, trauma and certain cancers.

In 2010, Dr. Ochoa accepted the offer of becoming the Medical and Scientific Director for Nestlé HealthCare Nutrition USA and eventually chief medical officer for Nestle Health Science in North America. Dr. Ochoa has published over 120 manuscripts including chapters and peer-reviewed articles in prestigious journals. His work at Nestle Health Science has focused on demonstrating the value of specialized nutrition aimed at meeting the distinct nutrition requirements of patients with different illnesses.

Eddie Power

Eddie Power

Head US Medical Affairs, Pfizer Essential Health
Pfizer

Read more

More information coming soon...

Suzanne Belinson

Suzanne Belinson

Executive Director, Clinical Markets
Blue Cross Blue Shield Association

Read more

Suzanne Belinson, Ph.D., M.P.H, is the Executive Director of Clinical Markets at the Blue Cross and Blue Shield Association (BCBSA), a national federation of 36 independent community-based and locally operated Blue Cross and Blue Shield companies. The Blue system is the nation’s largest health insurer covering over 100 million- one-in-three Americans. As the Executive Director, Dr. Belinson leads the sales and market development for products and services developed within the Office of Clinical Affairs. In addition, as part of the leadership team in the Office of Clinical Affairs she focuses on the development of emerging programs and services that enhance value and brand leadership for the independent BCBS Plans.

Before joining BCBSA, Dr. Belinson served as a NIH Clinical Cancer Fellow at Northwestern University where her work focused on community based interventions. Dr. Belinson developed and tested community based models for cervical cancer screening with both domestic and international applications. Dr. Belinson continues to serve as adjunct faculty at Northwestern University.

Dr. Belinson received her bachelor’s degree from Cleveland State University, and a PhD in Epidemiology from the University of North Carolina at Chapel Hill. She also holds a Masters in Public Health from the University of Pittsburgh.

John Graham

John Graham

Vice President and Head, Value Evidence and Outcomes
GSK

Read more

John Graham is a Vice President at GlaxoSmithKline and leads the Value Evidence and Outcomes (VEO) organization within GSK’s R&D division. The VEO organization is accountable for providing strategic input into the progression of assets as well as ensuring the value demonstration through evidence generation of the assets that do progress. This evidence includes accountability for Real World Evidence across GSK products and across all regions globally. In addition, his organization is accountable for GSK’s Patient Centered Outcomes and alignment with Patients in Partnership.

John sits on various Advisory Boards relating to Real World Evidence including the National Academies of Science working group on RWE, OPERAND, as well as the RWE Forum. He has published scientific communications across cardiovascular and metabolic diseases and across both clinical as well as RWE areas.

John joined GSK in 2014 as the Vice President, CV/Met, NS, Rare Disease VEO and then was promoted to his current role as the Head of the organization in November of 2015. He is located in the GSK R&D HUB in Collegeville, PA. Prior to GSK, John worked for over 16 years at Bristol-Myers Squibb where he was most recently the Head of the U.S. HEOR group and previously had roles across R&D and commercial with both Global and local accountabilities. Prior to Industry John worked in academia most recently as Assistant Professor of Clinical Pharmacy at St. Louis College of Pharmacy.

John holds a Doctorate of Pharmacy degree from Idaho State University and completed a Primary Care Residency at the University of Nebraska Medical Center.

Raymond Hill

Raymond Hill

Chairman and CEO
Corrona

Read more

Ray has spent the majority of his career in the healthcare field - first as a consultant and then running several divisions and companies.  In addition to his role as Chairman and CEO of Corrona, he is also Chairman of Prognos, a venture capital backed company that focuses on unlocking the power of lab data to improve treatment of patients.  Previously Ray was President of InVentiv Clinical, a major player in the clinical research space.  He has also served as CEO of PPD, and President of IMS Consulting and Services.  He lives in Princeton NJ, and is Board Chair of Row New York, a non-profit that pairs rowing with rigorous academic support for underprivileged kids in New York City.  Ray holds a BS from Cornell University, and an MEM from Duke University.

Jefferson Tea

Jefferson Tea

VP Medical & Scientific Affairs
Takeda Canada

Read more

More information coming soon...

Gary Kaplan

Gary Kaplan

Vice President of Medical Affairs Research
Clinical Score

Read more

Gary Kaplan is Vice President of Medical Affairs Research at Clinical SCORE. He has more than thirty years of professional experience as a statistician for market research and developer of cutting-edge approaches to business challenges and market sizing models, as well as a specialized focus on conversion of corporate business problems to useable designs.

Previously, Gary was the Chief Operating Officer for Leger Marketing/TRIG (a Canadian leader in public opinion polling and market research), the Executive Vice President at TNS and Research, and an Account Executive at Chilton Research Services.

He holds a Master of Science in Urban Studies with a major in Research Modeling and a Bachelor of Science in Psychology, both from Tulane University in New Orleans, LA, and a Master of Science in Applied Statistics from Temple University, Philadelphia, PA.

www.medicalaffairsperspectives.com

Luca Dezzani

Luca Dezzani

Global Brand Medical Director
Novartis

Read more

Luca Dezzani is a medical doctor with more than 10 years’ experience in healthcare, both in clinical practice as a Physician, and in the pharmaceutical industry. He have covered roles at national, regional and global level in both Europe and North America. Luca currently serves as Global Medical Director at Novartis Oncology and has an extensive experience in medical affairs.

Eric Wittbrodt

Eric Wittbrodt

Director HEOR
AstraZeneca

Read more

Eric is Director, Health Economics and Outcomes Research for Metabolics at AstraZeneca in Wilmington, DE. Eric received his Doctor of Pharmacy degree from the University of Michigan and subsequently completed clinical pharmacy residencies at Thomas Jefferson University Hospital and the Philadelphia College of Pharmacy and Science and a research fellowship in critical care at the University of Minnesota. In 2013, he earned a Master’s in Public Health Leadership from the University of North Carolina at Chapel Hill. After a career as pharmacy school faculty, Eric joined the pharmaceutical industry and has been employed by TAP/Takeda, Daiichi Sankyo, and by AstraZeneca since 2016.

Kathy Foris

Kathy Foris

Head of Medical Neurology
UCB

Read more

More information coming soon...

Gema Parlange

Gema Parlange

Vice President, Access Consulting
PAREXEL

Read more

Gema is the Global Head of Access Consulting, the Market Access unit of PAREXEL, managing an international team of 150 professionals, including senior service line leaders and recognized experts, covering all aspects of pricing, reimbursement, heath economics, evidence evaluations and HEOR. Responsible for the overall strategy, expansion and business direction of the unit.

Leanne Larson, MHA

Leanne Larson, MHA

Corporate Vice President & WW Head, Real-World Evidence Strategy
PAREXEL Consulting

Read more

Leanne Larson, Vice President, Evidence Development at PAREXEL Consulting, has over twenty-five years’ experience in healthcare, featuring extensive work in pharmaceutical product development and marketing, and in healthcare technology and operational consulting. Since 1993, Leanne has been an industry leader in developing and leading patient registries and other outcomes research programs, and in advancing the science and application of outcomes research throughout the pharmaceutical, biotech, and medical device industries.

In health economic and outcomes research studies covering a broad spectrum of technologies and therapies, Leanne has been involved in all aspects of project design, management, data analysis, and reporting. She has orchestrated retrospective and prospective studies of pharmacoeconomic outcomes touching upon cost of illness, quality of life, and other patient‑centered value measures and indicators. Her research has examined both the clinical relevance and market potential of new drugs and devices, with a strong focus on managed care populations. Leanne has also worked closely with hospitals and physicians, helping them incorporate outcomes measurement within their quality and performance-improvement systems. She publishes and speaks widely on a variety of topics related to outcomes research.

Prior to joining PAREXEL, Leanne served as VP, Strategic Development at Quintiles/Outcome, and as VP, Cancer Intelligence with Sg2 Healthcare Intelligence, where she led their Cancer Program, tracking emerging trends and technologies impacting cancer care, and working with cancer programs across the country to optimize care delivery. Prior to Sg2, Leanne led the Registry Consulting group at ICON Lifecycle Sciences (formerly Ovation Research Group) for over 14 years, and also held positions in Ernst & Young’s Life Sciences and Pharmaceuticals consulting practice, and as a Senior Health Science Coordinator in Digestive Diseases with Merck and Co.

Leanne holds a Master of Health Administration from Governors State University and a Bachelor of Science in Community Health from the University of Illinois. She is also an Instructor in Health Service Systems at the Keller Graduate School of Management, and is a Charter Member of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR), as well as an Invited Reviewer for The Center for Disease Control and Prevention (CDC).

Dr. Pritesh Gandhi, PharmD

Dr. Pritesh Gandhi, PharmD

Vice President-Medical Affairs
Alnylam Pharmaceuticals

Read more

Dr. Pritesh Gandhi, PharmD, is Vice President-Medical Affairs at Alnylam Pharmaceuticals, where he leads the execution of key clinical imperatives. Dr. Gandhi joined Alnylam in 2014, coming from Sanofi, where he most recently served as Associate Vice President of Global Medical Affairs. Prior to Sanofi, Dr. Gandhi held leadership positions at Alexion Pharmaceuticals and Millennium Pharmaceuticals (now Takeda Oncology). He received his Doctor of Pharmacy at the Massachusetts College of Pharmacy and Health Sciences and completed a Pharmacy Practice residency at the University of Illinois, Chicago.

Usman Iqbal MD, MPH, MBA

Usman Iqbal MD, MPH, MBA

Senior Director, Medical Affairs & HEOR
Trevena, Inc.

Read more

Usman Iqbal MD, MPH, MBA is a Senior Director, Medical Affairs & HEOR at Trevena, Inc. Usman has 12+ years of diverse experience spanning clinical medicine, R&D/Med AFF, Health economics & outcomes research across academia and biopharmaceutical. His experience spans number of different therapeutic areas including Neuroscience, as Senior Medical Affairs Leader at AstraZeneca, and Oncology, as former Head of Sanofi Oncology, Global Evidence & Value Development (GEVD). As part of both R&D and Med Affairs in different hybrid roles, Usman has built several transversal medical affairs platforms including Portfolio Prioritizations, Integrated Medical Affairs Planning & Execution, and end-to-end Evidence generation based on Stakeholder engagement, Market insights and Relative Medical Value Assessment Platforms. Prior to working in the industry that also includes Amgen and Boehringer Ingelheim, Usman was at the Boston University Health Outcomes Technology Group as a senior research fellow and served as a research consultant for Veterans Affairs Pharmacy Benefit Management (VA-PBM), the Centers for Medicare &, Medicaid Services’ Health Outcomes Survey Initiative (CMS-HOS), the Agency for Healthcare Research and Quality (AHRQ), and the National Committee for Quality Assurance (NCQA). Usman is a certified coach practitioner and currently serving as an advisor to several academic and health care think tanks.

Jim Robinson

Jim Robinson

President US, Astellas

Read more

More information coming soon...

Fabrice Chouraqui

Fabrice Chouraqui

President US, Novartis

Read more

Fabrice Chouraqui is currently working as President of Novartis Pharmaceuticals Corporation.

Fabrice has 20 years of experience in the Pharmaceutical industry, having worked in Research & Development, Commercial and General Management positions in Europe, North America, Asia and Latin America. Prior to joining Novartis in 2010, Fabrice worked for Bristol-Myers Squibb and Hoechst Marion Roussel.

Fabrice holds a Master in Science and a Doctorate in Pharmacy from the University of Paris as well as an MBA degree from INSEAD.

Paul Navarre

Paul Navarre

CEO, Ferring Holding

Read more

Paul Navarre is the Chief Executive Officer of Ferring Holding Inc., the U.S. subsidiary of Ferring Pharmaceuticals (The Ferring Group). Ferring Holding Inc. has more than 800 employees and turnover of over $700M.

Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. Ferring identifies, develops and markets innovative products in the fields of reproductive health, urology, gastroenterology, endocrinology, women’s health and orthopaedics.

An accomplished senior executive, Mr. Navarre has built a track record of success spanning 25 years including experience in fast-moving consumer goods and pharmaceuticals. He has served in key strategic positions responsible for operations in Europe, Asia, Africa, Middle East and the U.S. A French national, he has lived and worked in France, Italy, the UK, Switzerland and the U.S.A.

Before joining Ferring, Mr. Navarre was President of International Operations for Allergan. He began his career at Procter and Gamble where over 15 years he held multiple leadership positions in the company’s consumer goods and pharmaceuticals divisions.

Mr. Navarre has solid track record of delivering top line growth in the specialty pharmaceutical business through commercial innovation and customer centric approaches. He is recognized as an authentic visionary leader with the ability to attract and manage multi-functional talents.

Mr. Navarre and his wife have been married for 23 years. They have 4 children and live in New York.

Sue Mahony

Sue Mahony

SVP & President, Lilly Oncology

Read more

Sue Mahony, Ph.D., became president of Lilly Oncology in March 2011. She is also a senior vice president for Eli Lilly and Company and a member of the company’s executive committee.

In May 2009, she was appointed senior vice president, human resources and diversity for Lilly. Previously, she led Lilly’s operations in Canada.

Mahony was born and educated in the United Kingdom, where she obtained a Bachelor of Science degree in pharmacy from Aston University in Great Britain. She obtained a Ph.D. in pharmacy in the Cancer Research Campaign Experimental Chemotherapy Group also at Aston University, and a master’s degree in business administration from the London School of Business. In 2012, Sue received an honorary doctorate from Aston University.

Mahony joined Lilly in 2000 after more than a decade in sales and marketing roles in the United Kingdom and Europe for Schering-Plough, Amgen and Bristol-Myers Squibb. Since joining Lilly, Mahony has held executive leadership roles in product development, six sigma, human resources and general management, with global and operational responsibilities for North America, Europe, Japan and China.

In 2010, Mahony was recognized as one of the Indianapolis Business Journal’s “Women of Influence.” Mahony served on the board of the United Way of Central Indiana from 2010 to 2012 and has served on the Board of Directors of Park Tudor School since 2015. In December 2017, Mahony joined the Board of Directors of Assembly Biosciences, Inc.

Sue and her husband, John, have two children: Thomas and Rebecca.

Stephen Ubl

Stephen Ubl

President & CEO, PhRMA

Read more

Stephen Ubl is president and chief executive officer of Pharmaceutical Research and Manufacturers of America (PhRMA), which represents America's leading biopharmaceutical research companies. Mr. Ubl leads PhRMA's work preserving and strengthening a health care and economic environment that encourages medical innovation, new drug discovery, and access to life-saving medicines. If anyone can find areas of agreement with the critics, or at least work productively with them, it may be Mr. Ubl," the New York Times' Robert Pear wrote in February 2016. "He is more conversant with the intricacies of health policy, and more adept at the politics." He is routinely recognized as one of Washington’s most effective advocates, and, in 2017, was named for the second year in a row to Modern Healthcare’s “100 Most Influential People in Healthcare.” In 2016, he was named a Top Lobbyist by The Hill and a top health influencer by Medical Marketing & Media and PR Week magazines.

Bharat Tewarie

Bharat Tewarie

Executive Vice President, Chief Marketing Officer, UCB

Read more

Bharat Tewarie joins UCB with 27 years of experience in the pharma and biotech industry. He has acquired impressive worldwide expertise while leading global business unit teams to great success. His past experience in domains such as immunology and neurology are a great match to UCB’s core focus areas. His knowledge of markets around the world is also key to helping UCB prepare for future product launches. Trained as a medical doctor (MD), Bharat Tewarie also has an extensive background in multiple aspects of pharmaceutical management, including P&L responsibility, business development, sales, global marketing, clinical research and medical affairs. He has dedicated his career to better understanding patients living with chronic diseases and how to best meet their needs. At UCB Bharat heads the Global Strategic Marketing Practice and is a member of the Executive Committee.

Rob Scott

Rob Scott

VP Development and Chief Medical Officer, Abbvie

Read more

Dr Rob Scott is Zimbabwean born and studied medicine at the University of Cape Town. For thirty years Rob has held leadership positions in global Pharma, starting with J&J in South Africa. As the Global Head of CV and Metabolic at Pfizer he was responsible for what was then the world’s largest pharmaceutical product and the largest cardiovascular product – Lipitor and Norvasc. As Executive Vice President of R&D at AtheroGenics in Atlanta Georgia, he designed and implemented the first large cardiovascular outcomes study to be wholly performed by a small biotech. As Chief Medical Officer and Head of Development of Cerenis Therapeutics in Toulouse, France, Rob advanced the science of synthetic HDL. At Amgen, Rob ran the Cardiovascular, Metabolic, Nephrology, Bone, Inflammation and Neuroscience Therapeutic Areas. He also created the Development Design Center, a Center of Excellence focused on using predictive analytics for designing and implementing clinical trials. Rob is currently the Chief Medical Officer and Head of Development at Abbvie. In this role, he is a board member of Transcelerate and a member of the PhRMA Biomedical Advisory Committee. Rob was a member of the FDA Cardiac and Renal Drug Advisory Committee from 2012 to 2016 and also served on the Endocrine and Metabolic Advisory Committee. Rob has been involved with every therapeutic area and mode of drug delivery as well as both small molecules and biologics. He invented and developed the first drug combination to simultaneously treat two different disease states - Caduet.

Bob Oliver

Bob Oliver

President & CEO, V ClinBio

Read more

Bob managed a $6B P&L at Otsuka while managing a diverse and growing product portfolio across the cardio-renal, neuroscience, oncology, and medical device markets. Having compiled more than 25 years of experience in the pharmaceutical industry, across commercial and general management roles for premium companies within industry he was instrumental in building ABILIFY®, Abilify Maintena®, SAMSCA®, SPRYCEL® and Rexulti®. As Vice President and Global Business Manager for Oncology at Wyeth, he led the global launch of Torisel for RCC and later assumed responsibility for U.S. Commercial Operations. Bob began his career in pharmaceuticals with Johnson & Johnson where he held positions of increasing responsibility. During his tenure at Otsuka Bob held senior level executive roles including President & COO for North America and most recently Bob was in the role of President & CEO of Otsuka America Pharmaceuticals, Inc. He currently maintains the position of Board Chairman for Otsuka Canada. Bob is also Executive Advisor and a member of the Board of Directors for Hyalo Technologies; as well as Board Member of Neurotez both Biotech start ups. Previously Bob served on the board of Immunomedics a publicly traded company focused on Oncology.

Zhen Su

Zhen Su

SVP & CMO, EMDSerono

Read more

Dr. Zhen Su, Senior Vice President and Chief Medical Officer of North America for EMD Serono and Head of Global Medical Affairs Oncology (a.i.), heads the North American Medical Affairs organization as well as the medical strategy development and global medical team for the Oncology Franchise.

A physician executive with more than 20 years of experience, Dr. Su has strong clinical expertise in oncology, immuno-oncology and urology. He has held positions in academic and pharmaceutical medicine, including general management, clinical development, medical affairs and business development. Prior to EMD Serono, Dr. Su served in numerous leadership positions at Sanofi and GSK. Before joining industry, Dr. Su held several academic positions, including faculty roles at Duke University and University of Florida.

He has deep ties to the oncology community, having worked with leading oncologists at organizations globally. Dr. Su earned his MD degree from the Technical University of Dresden, Germany and completed his MBA training at the University of Toronto, Canada.

Bill Nolan

Bill Nolan

Vice president and general manager, Reimbursement, Access and Safety Services, MPRS, Biologics Hub services, McKesson Specialty Health

Read more

Bill Nolan has more than 25 years of healthcare and pharmaceutical marketing, product management, and healthcare administration experience and is currently vice president and general manager of the RA&SS, MPRS and Biologics HUB with McKesson Specialty Health. Bill joined McKesson in 2004.

Glenn Wada

Glenn Wada

President, CoverMyMeds

Read more

Glenn Wada is President of CoverMyMeds. As President, Glenn is responsible for driving the company's overall sales and operational performance. He brings enterprise expertise to the CoverMyMeds Executive Leadership Team, with a focus on delivering significant value to our global pharmaceutical manufacturer, health plan, pharmacy, provider and clinical system customers and partners.

Prior to joining CoverMyMeds, Glenn Wada spent a decade as a senior executive at global enterprise software provider, SAP, running a number of their large, multi-billion dollar business units. He also worked at EY, PeopleSoft, and several pharmaceutical & healthcare industry companies - helping those companies to innovate and grow while driving exponential growth.

Glenn has served as a Board Member for Special Olympics of Pennsylvania, on the Executive Committee for The Haverford School in Pennsylvania, and is eager to find similar civic / philanthropic opportunities in Columbus.

Marcello Damiani

Marcello Damiani

Chief Digital Officer, Moderna Therapeutics

Read more

Currently Moderna's Chief Digital Officer, Marcelo has a wealth of experience in both tech companies and Life Science companies and a true passion for making Digital a reality. He has 20-years experience working in the IT field, with the last 10 years being spent in leadership roles for multinational companies in Europe and tin the U.S. Prior to joining Moderna Therapeutics, Marcello has been instrumental in conceiving and building creative IT solutions to help solve business challengers, first at Motorola and then at bioMerieux and now at Moderna Therapeutics. His expertise is in visioning, strategizing and implementing innovative programs to update and streamline the digital landscapes. He is known for his ability to transform a company's Information flow, and ultimately improving the product and the company's processes through digitization.

Mr. Damiani possesses a Master of Science degree in Information Systems Architecture from the University of Toulouse in France, and an international Executive MBA through TRIUM, an alliance of three of the world's top universities: the London School of Economics, New York University Stern Business School and the HEC School of Management in Paris.

End-to-end Customer Experience & Digital Engagement


Danielle Salowski

Danielle Salowski

Industry Manager, Facebook Health

Read more

Danielle Salowski leads the Health Industry Vertical at Facebook, where her team is focused on defining go-to-market strategies for advertising and innovation in the Health space. Facebook Health’s mission is to connect people to the information or services they need to improve lives and create better health outcomes. Prior to joining Facebook, Danielle spent 11 years in the Digital and Social Media space across various roles at Twitter, CafeMom and News Corp. Danielle graduated from Villanova University with a degree in Communication.

Tricia Brown

Tricia Brown

Executive Director, Leader of US Promotion Organization, Merck

Read more

More information coming soon...

John Lineen

John Lineen

Global Channel Lead: Web & Mobile, GSK

Read more

More information coming soon...

Michael Suesserman

Michael Suesserman

Vice President, Marketing, Regeneron

Read more

Mike joined Regeneron in 2015 as Vice President, Marketing, overseeing both the in-line products as well as those in development. Over the past year Mike oversaw the launch of both Kevzara® (sarilumab) for rheumatoid arthritis and Dupixent® (dupilumab) for atopic dermatitis. Mike was instrumental in Regeneron’s move to a business unit model and now runs both the Ophthalmology and Cardio-metabolic Commercial Business Units.

Mike spent the bulk of his biopharma career at Pfizer in roles of increasing responsibility. He led the US and Global Marketing Teams for Pfizer’s blockbuster brand, Lipitor (atorvastatin) and oversaw the Global marketing of Viagra® (sildenafil citrate) while leading the Global Urology/Sexual Health Franchise. Mike was also Vice President of the Managed Care Business Unit.

After Pfizer, Mike focused on more entrepreneurial ventures. In 2011 he joined HarkHealth, a privately funded IT start-up as President, taking a “back of the envelope” concept to an in-market offering. In 2013, Mike joined Cello Health as Managing Director, Early Product Commercialization, working with companies to ensure the products they are developing will achieve commercial success.

Mike has Board of Directors experience, having served from 2014 to 2016 on the Board of Directors of Repros Therapeutics Inc., a NASDAQ listed development stage biopharmaceutical company focused on the development of oral small molecule drugs for major unmet medical needs in male and female health.

Mike holds a BA from Clark University and an MBA from Kelley School of Business.

Deb Hussain

Deb Hussain

Senior Director of Marketing, MCE Team Leader, Lilly

Read more

More information coming soon...

David Blair

David Blair

Head of Industry, Healthcare, Google

Read more

David Blair is Head of Industry for Health at Google. He leads a team that provides thought leadership, digital marketing strategies, insights, and cross-platform advertising solutions utilizing Google’s search, content network, YouTube, mobile, programmatic and analytics platforms for the world’s leading pharmaceutical and consumer health companies. Prior to Google, David was General Manager/SVP of Provider Solutions at Everyday Health.

David began his digital career in 1997 at iVillage as Vice President of Strategic Sponsorships where he pioneered many of the first digital marketing initiatives with Fortune 500 companies including P&G, Coke, Ford, Kimberly Clark, Kellogg’s and Fuji Film. He moved into the digital health space in 2001 as SVP/Group Publisher for Johnson & Johnson’s BabyCenter.com and was SVP of Ad Sales for Revolution Health, before the merger with Everyday Health in 2008.

Blair serves on the Google Healthcare Advisory Board, was named one of the top 40 Healthcare Transformers in the US by Medical Marketing & Media in 2015 and was a juror for the 2016 Clio Health Awards. He is a frequent keynote speaker at major agencies and industry events, most recently the IMCAS World Congress; Cannes Lions Health, American Heart Association, and Cleveland Clinic’s Patient Experience Summit.

Patient Potential, Value & Support


Scott Williams

Scott Williams

Vice President, Head of Global Patient Advocacy and Strategic Relationships, EMD Serono

Read more

More information coming soon...

Martha Orzechowski

Martha Orzechowski

Global Director, Oncology Patient Group Relations, AstraZeneca

Read more

More information coming soon...

Paul Gileno

Paul Gileno

Founder/President, US Pain Foundation inc.

Read more

More information coming soon...

Tolga Tanguler

Tolga Tanguler

President, North America, Rare Diseases, Pfizer

Read more

Tolga Tanguler is the Regional President, North America for Rare Diseases at Pfizer. In this role, Tolga leads an organization of more than 200 colleagues across marketing, sales, access, medical and corporate affairs and a portfolio of 6 assets to ensure they are focused on one objective: to transform patients’ lives. A key focus is to ensure that the engagement and experience of rare disease patients and their families are at the forefront of all programs; while ensuring the organization is prepared for the next phase of scientific breakthroughs, including gene therapy.

Tolga has more than 15 years of experience in the global pharmaceutical industry, including leadership roles in both developed markets such as the US, Japan and the Nordics and emerging economies including Africa/Middle East and Latin America. Most recently, Tolga was the Vice President, Global Marketing for ELIQUIS. Throughout these various assignments, the organizations led by Tolga were recognized for their rapid growth performance, as well as their strong culture that led to a significant improvement in colleague engagement. 

Tolga has Bachelor of Science degrees in Economics & Finance from University of Istanbul, and a Masters of Business Administration in Marketing and Supply Chain from Michigan State University. He also has a Post Graduate Degree in Marketing from the University of California. Tolga was recently appointed as a member of the Board of Directors of the National Association of Specialty Pharmacy.

Andre Cote

André Côté

VP / COO - Chief Operating Officer, Commercial Capabilities and Customer Experience, Eli Lilly Canada

Read more

Mr. André Côté holds the position of VP & Chief Operating Officer - Commercial Capabilities and Customer Experience for Eli Lilly Canada Inc. In this role, he is responsible for enhancing the company’s customer facing capabilities, and improving the experience the organization provides for patients, healthcare professionals and payers. Mr. Côté is also a member of the Senior Management Team of Eli Lilly Canada.

Since joining Eli Lilly Canada in 1993 as a Sales Representative, Mr. Côté has held a number of progressive roles in Canada within the Sales, Operations, Learning and Development, and Corporate Affairs organizations, including Government and Economic Affairs Manager, Sales & Operations Director for Quebec, as well as Vice President of Sales.

Mr. Côté has also held various Global leadership positions at Lilly in Pricing, Reimbursement & Access, as well as Global Brand Marketing Strategy. He was also a member of the Senior Leadership Teams for Global Corporate Affairs, and the Global BioMedicines Business Unit. Most recently, Mr. Côté held the position of Senior Director, Global Customer Support Programs at Lilly Corporate Center in Indianapolis, overseeing corporate strategy and capabilities development within the organization.

Prior to joining Eli Lilly Canada, Mr. Côté obtained a Bachelor’s Degree in Business and Marketing in 1993 from the Université Laval in Quebec.

Mr. Côté is fluent in both English and French.

Matt Zeller

Matt Zeller

VP, Head of US Patient and Specialty Services, Novartis

Read more

More information coming soon...

Steve Morin

Steve Morin

Health Programs Coordinator, Office of Health & Constituent Affairs, FDA

Read more

More information coming soon...

Samantha John

Samantha John

Head – UCB Cares, UCB

Read more

More information coming soon...

External Innovation & Collaboration


Alexis Normand

Alexis Normand

Head of B2B, Nokia Health

Read more

More information coming soon...

Jerry Berger

Jerry Berger

Senior Manager, Healthcare, Samsung

Read more

Jerry Berger possesses over 20 years of IT marketing within the healthcare space. He is currently the Senior Manager for Marketing for Samsung Healthcare where he markets mobility and wearable solutions to hospitals, long-term care, pharmas and consumer health organizations. Prior to his current tenure at Samsung, he worked for Siemens Healthcare and marketed healthcare analytics and value-added services to the acute hospital space. Jerry possesses an MBA from The American University in Washington DC.

Andrew Ploszay

Andrew Ploszay

Head, Digital Innovation & Strategic Partnerships, GSK

Read more

More information coming soon...

Paul Lazzaro

Paul Lazzaro

Vice President, US Primary Care Sales & Key Accounts, Horizon Pharma plc

Read more

More information coming soon...

Terri Young

Terri Young

Worldwide General Manager, Cardiology, Bristol-Myers Squibb

Read more

More information coming soon...

All Speakers


Rob Scott MD

Rob Scott MD

Chief Medical Officer, VP Global Development
Abbvie

Read more

Dr Rob Scott is Zimbabwean born and studied medicine at the University of Cape Town. For thirty years Rob has held leadership positions in global Pharma, starting with J&J in South Africa. As the Global Head of CV and Metabolic at Pfizer he was responsible for what was then the world’s largest pharmaceutical product and the largest cardiovascular product – Lipitor and Norvasc. As Executive Vice President of R&D at AtheroGenics in Atlanta Georgia, he designed and implemented the first large cardiovascular outcomes study to be wholly performed by a small biotech. As Chief Medical Officer and Head of Development of Cerenis Therapeutics in Toulouse, France, Rob advanced the science of synthetic HDL. At Amgen, Rob ran the Cardiovascular, Metabolic, Nephrology, Bone, Inflammation and Neuroscience Therapeutic Areas. He also created the Development Design Center, a Center of Excellence focused on using predictive analytics for designing and implementing clinical trials. Rob is currently the Chief Medical Officer and Head of Development at Abbvie. In this role, he is a board member of Transcelerate and a member of the PhRMA Biomedical Advisory Committee. Rob was a member of the FDA Cardiac and Renal Drug Advisory Committee from 2012 to 2016 and also served on the Endocrine and Metabolic Advisory Committee. Rob has been involved with every therapeutic area and mode of drug delivery as well as both small molecules and biologics. He invented and developed the first drug combination to simultaneously treat two different disease states - Caduet.

Sotirios Stergiopoulos

Sotirios Stergiopoulos

CMO, Senior Vice President and Head of Global Medical Affairs
Ipsen

Read more

Dr. Sotirios Stergiopoulos is Chief Medical Officer, Senior Vice President and Head of Global Medical Affairs and a member of the R&D Leadership team at Ipsen BioScience. Sotirios has an extensive experience in directing medical affairs worldwide strategies and plans and a solid expertise in Oncology drug development.

Dr. Stergiopoulos earned his M.D at the University of Medical Sciences of Poznan, Poland. He completed his residency in Internal Medicine at the Albert Einstein College of Medicine (NY), a clinical and research fellowship in Medical Genetics at Harvard Medical School and a research fellowship at National Institutes of Health where he had received an Intramural Research Training Award.

Dr. Stergiopoulos is currently an Attending Physician in the Department of Internal Medicine at Jacobi Medical Center, Albert Einstein College of Medicine (NY). He has been elected as President of the Board of Governors of the Accreditation Council of Medical Affairs and he holds a Masters in Biotechnology Enterprise and Entrepreneurship (MBEE) from The Johns Hopkins University (Baltimore, MD). Sotirios is a Fellow of the New York Academy of Medicine as well as the Royal Society of Medicine (UK). He also is a Member of the American Association of Cancer Research, American Society of Clinical Oncology, and sits on multiple Boards.

Zhen Su

Zhen Su

Chief Medical Officer, North America
EMD Serono

Read more

Dr. Zhen Su, Senior Vice President and Chief Medical Officer of North America for EMD Serono and Head of Global Medical Affairs Oncology (a.i.), heads the North American Medical Affairs organization as well as the medical strategy development and global medical team for the Oncology Franchise.

A physician executive with more than 20 years of experience, Dr. Su has strong clinical expertise in oncology, immuno-oncology and urology. He has held positions in academic and pharmaceutical medicine, including general management, clinical development, medical affairs and business development. Prior to EMD Serono, Dr. Su served in numerous leadership positions at Sanofi and GSK. Before joining industry, Dr. Su held several academic positions, including faculty roles at Duke University and University of Florida.

He has deep ties to the oncology community, having worked with leading oncologists at organizations globally. Dr. Su earned his MD degree from the Technical University of Dresden, Germany and completed his MBA training at the University of Toronto, Canada.

Sandy Leonard

Sandy Leonard

Vice President of Medical Evidence & Observational Research
AstraZeneca

Read more

More information coming soon...

Pol Vandenbroucke

Pol Vandenbroucke

Vice President, Medical Strategy
Pfizer

Read more

Vice President, Medical Strategy, Pfizer Inc., in charge of Global Patient Affairs, the Centers of Excellence for Pediatrics, Diversity in Clinical Trials and Healthy Aging, and the External Bioethics Advisory Panel.

Member of the Board of BIO Ventures for Global Health, and of the American Federation for Aging Research; Member of the Advisory Board of the Steve Biko Centre for Bioethics, University of the Witwatersrand, Johannesburg, South Africa, and of the Keck Graduate Institute, Claremont, CA; Fellow of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Medicine of the United Kingdom and member of its Fellowship and Awards Committee; Module Coordinator Medical Affairs in Medicines Development, IFAPP Academy and King’s College London.

Dr. Vandenbroucke’ s career has been dedicated to Clinical Development, Medical Affairs and Marketing and has included stints in the U.S., Europe, Asia, and Latin America. Before his current position, he was responsible for Medical Affairs of Pfizer’s Essential Health portfolio in North America and he previously also led Clinical Development of all Pfizer compounds in Asia, Central and Eastern Europe, Latin America, and Africa-Middle East and of Pfizer’s Established Products globally. He was also responsible for developing compounds specifically for diseases of the developing world, such as malaria and river blindness.

Prior appointments include Vice President, Medical and Regulatory Affairs, Canada/Latin America/Africa-Middle East, Senior Vice President, Medical Division Pfizer Japan, based in Tokyo, Director of Medical Operations, Asia and Australia/NZ for Pfizer, based in Hong Kong, and Medical Director, Lipitor based in New York, responsible for the international clinical development program of Lipitor.

Before joining Pfizer, Dr. Vandenbroucke was Medical Director, Sterling-Winthrop International; Cardiovascular and CNS Disease Brand Manager at Novartis Mexico, and Brand Assistant at Procter & Gamble Mexico.

He holds a Medical Degree from the Catholic University of Louvain (Belgium), an MBA degree from the Instituto Tecnológico Autónomo de México (ITAM), and an MSc (First Honors) from Hibernia College (Ireland). He is a member of the Pfizer Latino PCC Leadership Team. He is fluent in Dutch, Spanish, English, French, German and basic Japanese.

Scott Williams

Scott Williams

Vice President, Head of Global Patient Advocacy and Strategic Relationships
EMD Serono

Read more

Scott leads our patient advocacy and engagement team as Vice President, Head of Global Patient Advocacy and Strategic Relationships. Prior to joining EMD Serono, Scott held leadership positions at the American Cancer Society Cancer Action Network and Men’s Health Network.

Prior to his patient advocacy experience, Scott held positions in external relations at Sanofi Pasteur and was an analyst at PharmaStrat, a managed care market research company. Scott holds a M.P.A., Executive Leadership from the American University in Washington, D.C., and earned a B.A. cum laude in Political Science from Moravian College in Bethlehem, Pennsylvania. He is based in Washington, DC.

Vivian Herrera

Vivian Herrera

Executive Director, Head of HEOR Payer Strategy
Novartis

Read more

Vivian Herrera is Executive Director and Head of the Immunology & Dermatology, Migraine and HE&OR Payer Strategy Team, within the Department of Health Economics and Outcomes Research at Novartis Pharmaceuticals Corporation.

Vivian completed her Dental degree at Colegio Odontologico Colombiano where she practiced for 2 years. She furthered her education earning a dual masters degree at Columbia University in Public Health and International Affairs. She worked for 11 years on the payer side at Medco currently known as Express scripts in the Advanced Clinical and Science Research team. In her role there she worked on various retrospective and prospective studies in support of various corporate strategic initiatives. Her work was instrumental in identifying gaps and improving the diabetes and depression health programs. E-prescribing and physician detailing were successful initiatives with the help of Vivian’s predictive and regression models on patient and physician behavior. In addition, she was key in the renewal of one of the company’s largest clients by successfully completing a real world program evaluation where she earned Medco’s President Award. More recently she moved to the pharmaceutical industry working for Sanofi in the Global Evidence and Value Development team where she managed the analytic team for Rare diseases and Multiple Sclerosis. She has multiple publications and presentations on Medicare, Diabetes, Cardiovascular, Immunology and Dermatology and Neuroscience therapeutic areas.

Chris Keenan

Chris Keenan

Head, Worldwide Medical Customer Engagement, Medical Capabilities
BMS

Read more

A senior business leader with solid record of leading top performing business units and producing results that have positive impact on the bottom line and customer experience. Diverse worldwide management and operations expertise within financial services, insurance and pharmaceutical sectors. He is a sought-after presenter on topics such as striving for operational excellence, customer engagement and the power of unified data and analytics. Mr. Keenan has been honored by the Philadelphia Direct Marketing Association (PDMA) and the Canadian Direct Marketing Associations (CDMA) for his marketing and operational excellence along with numerous Bristol-Myers Squibb recognitions.

Juan Ochoa

Juan Ochoa

Chief Medical Officer, US
Nestlé

Read more

Dr. Juan Ochoa completed his first residency training in general Surgery with a focus on trauma in Colombia in 1988. He then came to the US to pursue his interests in basic research and was the first to demonstrate that excessive nitric oxide production in humans could explain the hemodynamic instability of sepsis. He began a second residency position at the general surgery program at the University of Pittsburgh in 1991.

In 1996, Dr. Ochoa completed his training and a fellowship in Multidisciplinary Critical Care holding a full time clinical practice in surgery and critical while also obtaining support from the National Institutes of health to continue his independent research on nitric oxide production in trauma and surgery patients. Upon returning to the University of Pittsburgh, Dr. Ochoa became Professor of Surgery and Critical Care and associate director for trauma services at UPMC. During his tenure at the University of Pittsburgh, his laboratory discovered the presence of cells that specialized in destroying the amino acid arginine, explaining why this nutrient is conditionally essential requiring replenishment in patients undergoing surgery or after trauma. In 2008, Ms. Jean Marx in SCIENCE (the journal) interviewed him about the discovery of arginine destruction by myeloid cells. His work has been essential at defining arginine deficiency as a cause of immune dysfunction in several illnesses including surgery, trauma and certain cancers.

In 2010, Dr. Ochoa accepted the offer of becoming the Medical and Scientific Director for Nestlé HealthCare Nutrition USA and eventually chief medical officer for Nestle Health Science in North America. Dr. Ochoa has published over 120 manuscripts including chapters and peer-reviewed articles in prestigious journals. His work at Nestle Health Science has focused on demonstrating the value of specialized nutrition aimed at meeting the distinct nutrition requirements of patients with different illnesses.

Eddie Power

Eddie Power

Head US Medical Affairs, Pfizer Essential Health
Pfizer

Read more

More information coming soon...

Suzanne Belinson

Suzanne Belinson

Executive Director, Clinical Markets
Blue Cross Blue Shield Association

Read more

Suzanne Belinson, Ph.D., M.P.H, is the Executive Director of Clinical Markets at the Blue Cross and Blue Shield Association (BCBSA), a national federation of 36 independent community-based and locally operated Blue Cross and Blue Shield companies. The Blue system is the nation’s largest health insurer covering over 100 million- one-in-three Americans. As the Executive Director, Dr. Belinson leads the sales and market development for products and services developed within the Office of Clinical Affairs. In addition, as part of the leadership team in the Office of Clinical Affairs she focuses on the development of emerging programs and services that enhance value and brand leadership for the independent BCBS Plans.

Before joining BCBSA, Dr. Belinson served as a NIH Clinical Cancer Fellow at Northwestern University where her work focused on community based interventions. Dr. Belinson developed and tested community based models for cervical cancer screening with both domestic and international applications. Dr. Belinson continues to serve as adjunct faculty at Northwestern University.

Dr. Belinson received her bachelor’s degree from Cleveland State University, and a PhD in Epidemiology from the University of North Carolina at Chapel Hill. She also holds a Masters in Public Health from the University of Pittsburgh.

John Graham

John Graham

Vice President and Head, Value Evidence and Outcomes
GSK

Read more

John Graham is a Vice President at GlaxoSmithKline and leads the Value Evidence and Outcomes (VEO) organization within GSK’s R&D division. The VEO organization is accountable for providing strategic input into the progression of assets as well as ensuring the value demonstration through evidence generation of the assets that do progress. This evidence includes accountability for Real World Evidence across GSK products and across all regions globally. In addition, his organization is accountable for GSK’s Patient Centered Outcomes and alignment with Patients in Partnership.

John sits on various Advisory Boards relating to Real World Evidence including the National Academies of Science working group on RWE, OPERAND, as well as the RWE Forum. He has published scientific communications across cardiovascular and metabolic diseases and across both clinical as well as RWE areas.

John joined GSK in 2014 as the Vice President, CV/Met, NS, Rare Disease VEO and then was promoted to his current role as the Head of the organization in November of 2015. He is located in the GSK R&D HUB in Collegeville, PA. Prior to GSK, John worked for over 16 years at Bristol-Myers Squibb where he was most recently the Head of the U.S. HEOR group and previously had roles across R&D and commercial with both Global and local accountabilities. Prior to Industry John worked in academia most recently as Assistant Professor of Clinical Pharmacy at St. Louis College of Pharmacy.

John holds a Doctorate of Pharmacy degree from Idaho State University and completed a Primary Care Residency at the University of Nebraska Medical Center.

Raymond Hill

Raymond Hill

Chairman and CEO
Corrona

Read more

Ray has spent the majority of his career in the healthcare field - first as a consultant and then running several divisions and companies.  In addition to his role as Chairman and CEO of Corrona, he is also Chairman of Prognos, a venture capital backed company that focuses on unlocking the power of lab data to improve treatment of patients.  Previously Ray was President of InVentiv Clinical, a major player in the clinical research space.  He has also served as CEO of PPD, and President of IMS Consulting and Services.  He lives in Princeton NJ, and is Board Chair of Row New York, a non-profit that pairs rowing with rigorous academic support for underprivileged kids in New York City.  Ray holds a BS from Cornell University, and an MEM from Duke University.

Jefferson Tea

Jefferson Tea

VP Medical & Scientific Affairs
Takeda Canada

Read more

More information coming soon...

Gary Kaplan

Gary Kaplan

Vice President of Medical Affairs Research
Clinical Score

Read more

Gary Kaplan is Vice President of Medical Affairs Research at Clinical SCORE. He has more than thirty years of professional experience as a statistician for market research and developer of cutting-edge approaches to business challenges and market sizing models, as well as a specialized focus on conversion of corporate business problems to useable designs.

Previously, Gary was the Chief Operating Officer for Leger Marketing/TRIG (a Canadian leader in public opinion polling and market research), the Executive Vice President at TNS and Research, and an Account Executive at Chilton Research Services.

He holds a Master of Science in Urban Studies with a major in Research Modeling and a Bachelor of Science in Psychology, both from Tulane University in New Orleans, LA, and a Master of Science in Applied Statistics from Temple University, Philadelphia, PA.

www.medicalaffairsperspectives.com

Luca Dezzani

Luca Dezzani

Global Brand Medical Director
Novartis

Read more

Luca Dezzani is a medical doctor with more than 10 years’ experience in healthcare, both in clinical practice as a Physician, and in the pharmaceutical industry. He have covered roles at national, regional and global level in both Europe and North America. Luca currently serves as Global Medical Director at Novartis Oncology and has an extensive experience in medical affairs.

Eric Wittbrodt

Eric Wittbrodt

Director HEOR
AstraZeneca

Read more

Eric is Director, Health Economics and Outcomes Research for Metabolics at AstraZeneca in Wilmington, DE. Eric received his Doctor of Pharmacy degree from the University of Michigan and subsequently completed clinical pharmacy residencies at Thomas Jefferson University Hospital and the Philadelphia College of Pharmacy and Science and a research fellowship in critical care at the University of Minnesota. In 2013, he earned a Master’s in Public Health Leadership from the University of North Carolina at Chapel Hill. After a career as pharmacy school faculty, Eric joined the pharmaceutical industry and has been employed by TAP/Takeda, Daiichi Sankyo, and by AstraZeneca since 2016.

Kathy Foris

Kathy Foris

Head of Medical Neurology
UCB

Read more

More information coming soon...

Gema Parlange

Gema Parlange

Vice President, Access Consulting
PAREXEL

Read more

Gema is the Global Head of Access Consulting, the Market Access unit of PAREXEL, managing an international team of 150 professionals, including senior service line leaders and recognized experts, covering all aspects of pricing, reimbursement, heath economics, evidence evaluations and HEOR. Responsible for the overall strategy, expansion and business direction of the unit.

Leanne Larson, MHA

Leanne Larson, MHA

Corporate Vice President & WW Head, Real-World Evidence Strategy
PAREXEL Consulting

Read more

Leanne Larson, Vice President, Evidence Development at PAREXEL Consulting, has over twenty-five years’ experience in healthcare, featuring extensive work in pharmaceutical product development and marketing, and in healthcare technology and operational consulting. Since 1993, Leanne has been an industry leader in developing and leading patient registries and other outcomes research programs, and in advancing the science and application of outcomes research throughout the pharmaceutical, biotech, and medical device industries.

In health economic and outcomes research studies covering a broad spectrum of technologies and therapies, Leanne has been involved in all aspects of project design, management, data analysis, and reporting. She has orchestrated retrospective and prospective studies of pharmacoeconomic outcomes touching upon cost of illness, quality of life, and other patient‑centered value measures and indicators. Her research has examined both the clinical relevance and market potential of new drugs and devices, with a strong focus on managed care populations. Leanne has also worked closely with hospitals and physicians, helping them incorporate outcomes measurement within their quality and performance-improvement systems. She publishes and speaks widely on a variety of topics related to outcomes research.

Prior to joining PAREXEL, Leanne served as VP, Strategic Development at Quintiles/Outcome, and as VP, Cancer Intelligence with Sg2 Healthcare Intelligence, where she led their Cancer Program, tracking emerging trends and technologies impacting cancer care, and working with cancer programs across the country to optimize care delivery. Prior to Sg2, Leanne led the Registry Consulting group at ICON Lifecycle Sciences (formerly Ovation Research Group) for over 14 years, and also held positions in Ernst & Young’s Life Sciences and Pharmaceuticals consulting practice, and as a Senior Health Science Coordinator in Digestive Diseases with Merck and Co.

Leanne holds a Master of Health Administration from Governors State University and a Bachelor of Science in Community Health from the University of Illinois. She is also an Instructor in Health Service Systems at the Keller Graduate School of Management, and is a Charter Member of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR), as well as an Invited Reviewer for The Center for Disease Control and Prevention (CDC).

Dr. Pritesh Gandhi, PharmD

Dr. Pritesh Gandhi, PharmD

Vice President-Medical Affairs
Alnylam Pharmaceuticals

Read more

Dr. Pritesh Gandhi, PharmD, is Vice President-Medical Affairs at Alnylam Pharmaceuticals, where he leads the execution of key clinical imperatives. Dr. Gandhi joined Alnylam in 2014, coming from Sanofi, where he most recently served as Associate Vice President of Global Medical Affairs. Prior to Sanofi, Dr. Gandhi held leadership positions at Alexion Pharmaceuticals and Millennium Pharmaceuticals (now Takeda Oncology). He received his Doctor of Pharmacy at the Massachusetts College of Pharmacy and Health Sciences and completed a Pharmacy Practice residency at the University of Illinois, Chicago.

Usman Iqbal MD, MPH, MBA

Usman Iqbal MD, MPH, MBA

Senior Director, Medical Affairs & HEOR
Trevena, Inc.

Read more

Usman Iqbal MD, MPH, MBA is a Senior Director, Medical Affairs & HEOR at Trevena, Inc. Usman has 12+ years of diverse experience spanning clinical medicine, R&D/Med AFF, Health economics & outcomes research across academia and biopharmaceutical. His experience spans number of different therapeutic areas including Neuroscience, as Senior Medical Affairs Leader at AstraZeneca, and Oncology, as former Head of Sanofi Oncology, Global Evidence & Value Development (GEVD). As part of both R&D and Med Affairs in different hybrid roles, Usman has built several transversal medical affairs platforms including Portfolio Prioritizations, Integrated Medical Affairs Planning & Execution, and end-to-end Evidence generation based on Stakeholder engagement, Market insights and Relative Medical Value Assessment Platforms. Prior to working in the industry that also includes Amgen and Boehringer Ingelheim, Usman was at the Boston University Health Outcomes Technology Group as a senior research fellow and served as a research consultant for Veterans Affairs Pharmacy Benefit Management (VA-PBM), the Centers for Medicare &, Medicaid Services’ Health Outcomes Survey Initiative (CMS-HOS), the Agency for Healthcare Research and Quality (AHRQ), and the National Committee for Quality Assurance (NCQA). Usman is a certified coach practitioner and currently serving as an advisor to several academic and health care think tanks.

Jim Robinson

Jim Robinson

President US, Astellas

Read more

More information coming soon...

Fabrice Chouraqui

Fabrice Chouraqui

President US, Novartis

Read more

Fabrice Chouraqui is currently working as President of Novartis Pharmaceuticals Corporation.

Fabrice has 20 years of experience in the Pharmaceutical industry, having worked in Research & Development, Commercial and General Management positions in Europe, North America, Asia and Latin America. Prior to joining Novartis in 2010, Fabrice worked for Bristol-Myers Squibb and Hoechst Marion Roussel.

Fabrice holds a Master in Science and a Doctorate in Pharmacy from the University of Paris as well as an MBA degree from INSEAD.

Paul Navarre

Paul Navarre

CEO, Ferring Holding

Read more

Paul Navarre is the Chief Executive Officer of Ferring Holding Inc., the U.S. subsidiary of Ferring Pharmaceuticals (The Ferring Group). Ferring Holding Inc. has more than 800 employees and turnover of over $700M.

Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. Ferring identifies, develops and markets innovative products in the fields of reproductive health, urology, gastroenterology, endocrinology, women’s health and orthopaedics.

An accomplished senior executive, Mr. Navarre has built a track record of success spanning 25 years including experience in fast-moving consumer goods and pharmaceuticals. He has served in key strategic positions responsible for operations in Europe, Asia, Africa, Middle East and the U.S. A French national, he has lived and worked in France, Italy, the UK, Switzerland and the U.S.A.

Before joining Ferring, Mr. Navarre was President of International Operations for Allergan. He began his career at Procter and Gamble where over 15 years he held multiple leadership positions in the company’s consumer goods and pharmaceuticals divisions.

Mr. Navarre has solid track record of delivering top line growth in the specialty pharmaceutical business through commercial innovation and customer centric approaches. He is recognized as an authentic visionary leader with the ability to attract and manage multi-functional talents.

Mr. Navarre and his wife have been married for 23 years. They have 4 children and live in New York.

Sue Mahony

Sue Mahony

SVP & President, Lilly Oncology

Read more

Sue Mahony, Ph.D., became president of Lilly Oncology in March 2011. She is also a senior vice president for Eli Lilly and Company and a member of the company’s executive committee.

In May 2009, she was appointed senior vice president, human resources and diversity for Lilly. Previously, she led Lilly’s operations in Canada.

Mahony was born and educated in the United Kingdom, where she obtained a Bachelor of Science degree in pharmacy from Aston University in Great Britain. She obtained a Ph.D. in pharmacy in the Cancer Research Campaign Experimental Chemotherapy Group also at Aston University, and a master’s degree in business administration from the London School of Business. In 2012, Sue received an honorary doctorate from Aston University.

Mahony joined Lilly in 2000 after more than a decade in sales and marketing roles in the United Kingdom and Europe for Schering-Plough, Amgen and Bristol-Myers Squibb. Since joining Lilly, Mahony has held executive leadership roles in product development, six sigma, human resources and general management, with global and operational responsibilities for North America, Europe, Japan and China.

In 2010, Mahony was recognized as one of the Indianapolis Business Journal’s “Women of Influence.” Mahony served on the board of the United Way of Central Indiana from 2010 to 2012 and has served on the Board of Directors of Park Tudor School since 2015. In December 2017, Mahony joined the Board of Directors of Assembly Biosciences, Inc.

Sue and her husband, John, have two children: Thomas and Rebecca.

Stephen Ubl

Stephen Ubl

President & CEO, PhRMA

Read more

Stephen Ubl is president and chief executive officer of Pharmaceutical Research and Manufacturers of America (PhRMA), which represents America's leading biopharmaceutical research companies. Mr. Ubl leads PhRMA's work preserving and strengthening a health care and economic environment that encourages medical innovation, new drug discovery, and access to life-saving medicines. If anyone can find areas of agreement with the critics, or at least work productively with them, it may be Mr. Ubl," the New York Times' Robert Pear wrote in February 2016. "He is more conversant with the intricacies of health policy, and more adept at the politics." He is routinely recognized as one of Washington’s most effective advocates, and, in 2017, was named for the second year in a row to Modern Healthcare’s “100 Most Influential People in Healthcare.” In 2016, he was named a Top Lobbyist by The Hill and a top health influencer by Medical Marketing & Media and PR Week magazines.

Bharat Tewarie

Bharat Tewarie

Executive Vice President, Chief Marketing Officer, UCB

Read more

Bharat Tewarie joins UCB with 27 years of experience in the pharma and biotech industry. He has acquired impressive worldwide expertise while leading global business unit teams to great success. His past experience in domains such as immunology and neurology are a great match to UCB’s core focus areas. His knowledge of markets around the world is also key to helping UCB prepare for future product launches. Trained as a medical doctor (MD), Bharat Tewarie also has an extensive background in multiple aspects of pharmaceutical management, including P&L responsibility, business development, sales, global marketing, clinical research and medical affairs. He has dedicated his career to better understanding patients living with chronic diseases and how to best meet their needs. At UCB Bharat heads the Global Strategic Marketing Practice and is a member of the Executive Committee.

Rob Scott

Rob Scott

VP Development and Chief Medical Officer, Abbvie

Read more

Dr Rob Scott is Zimbabwean born and studied medicine at the University of Cape Town. For thirty years Rob has held leadership positions in global Pharma, starting with J&J in South Africa. As the Global Head of CV and Metabolic at Pfizer he was responsible for what was then the world’s largest pharmaceutical product and the largest cardiovascular product – Lipitor and Norvasc. As Executive Vice President of R&D at AtheroGenics in Atlanta Georgia, he designed and implemented the first large cardiovascular outcomes study to be wholly performed by a small biotech. As Chief Medical Officer and Head of Development of Cerenis Therapeutics in Toulouse, France, Rob advanced the science of synthetic HDL. At Amgen, Rob ran the Cardiovascular, Metabolic, Nephrology, Bone, Inflammation and Neuroscience Therapeutic Areas. He also created the Development Design Center, a Center of Excellence focused on using predictive analytics for designing and implementing clinical trials. Rob is currently the Chief Medical Officer and Head of Development at Abbvie. In this role, he is a board member of Transcelerate and a member of the PhRMA Biomedical Advisory Committee. Rob was a member of the FDA Cardiac and Renal Drug Advisory Committee from 2012 to 2016 and also served on the Endocrine and Metabolic Advisory Committee. Rob has been involved with every therapeutic area and mode of drug delivery as well as both small molecules and biologics. He invented and developed the first drug combination to simultaneously treat two different disease states - Caduet.

Bob Oliver

Bob Oliver

President & CEO, V ClinBio

Read more

Bob managed a $6B P&L at Otsuka while managing a diverse and growing product portfolio across the cardio-renal, neuroscience, oncology, and medical device markets. Having compiled more than 25 years of experience in the pharmaceutical industry, across commercial and general management roles for premium companies within industry he was instrumental in building ABILIFY®, Abilify Maintena®, SAMSCA®, SPRYCEL® and Rexulti®. As Vice President and Global Business Manager for Oncology at Wyeth, he led the global launch of Torisel for RCC and later assumed responsibility for U.S. Commercial Operations. Bob began his career in pharmaceuticals with Johnson & Johnson where he held positions of increasing responsibility. During his tenure at Otsuka Bob held senior level executive roles including President & COO for North America and most recently Bob was in the role of President & CEO of Otsuka America Pharmaceuticals, Inc. He currently maintains the position of Board Chairman for Otsuka Canada. Bob is also Executive Advisor and a member of the Board of Directors for Hyalo Technologies; as well as Board Member of Neurotez both Biotech start ups. Previously Bob served on the board of Immunomedics a publicly traded company focused on Oncology.

Zhen Su

Zhen Su

SVP & CMO, EMDSerono

Read more

Dr. Zhen Su, Senior Vice President and Chief Medical Officer of North America for EMD Serono and Head of Global Medical Affairs Oncology (a.i.), heads the North American Medical Affairs organization as well as the medical strategy development and global medical team for the Oncology Franchise.

A physician executive with more than 20 years of experience, Dr. Su has strong clinical expertise in oncology, immuno-oncology and urology. He has held positions in academic and pharmaceutical medicine, including general management, clinical development, medical affairs and business development. Prior to EMD Serono, Dr. Su served in numerous leadership positions at Sanofi and GSK. Before joining industry, Dr. Su held several academic positions, including faculty roles at Duke University and University of Florida.

He has deep ties to the oncology community, having worked with leading oncologists at organizations globally. Dr. Su earned his MD degree from the Technical University of Dresden, Germany and completed his MBA training at the University of Toronto, Canada.

Bill Nolan

Bill Nolan

Vice president and general manager, Reimbursement, Access and Safety Services, MPRS, Biologics Hub services, McKesson Specialty Health

Read more

Bill Nolan has more than 25 years of healthcare and pharmaceutical marketing, product management, and healthcare administration experience and is currently vice president and general manager of the RA&SS, MPRS and Biologics HUB with McKesson Specialty Health. Bill joined McKesson in 2004.

Glenn Wada

Glenn Wada

President, CoverMyMeds

Read more

Glenn Wada is President of CoverMyMeds. As President, Glenn is responsible for driving the company's overall sales and operational performance. He brings enterprise expertise to the CoverMyMeds Executive Leadership Team, with a focus on delivering significant value to our global pharmaceutical manufacturer, health plan, pharmacy, provider and clinical system customers and partners.

Prior to joining CoverMyMeds, Glenn Wada spent a decade as a senior executive at global enterprise software provider, SAP, running a number of their large, multi-billion dollar business units. He also worked at EY, PeopleSoft, and several pharmaceutical & healthcare industry companies - helping those companies to innovate and grow while driving exponential growth.

Glenn has served as a Board Member for Special Olympics of Pennsylvania, on the Executive Committee for The Haverford School in Pennsylvania, and is eager to find similar civic / philanthropic opportunities in Columbus.

Marcello Damiani

Marcello Damiani

Chief Digital Officer, Moderna Therapeutics

Read more

Currently Moderna's Chief Digital Officer, Marcelo has a wealth of experience in both tech companies and Life Science companies and a true passion for making Digital a reality. He has 20-years experience working in the IT field, with the last 10 years being spent in leadership roles for multinational companies in Europe and tin the U.S. Prior to joining Moderna Therapeutics, Marcello has been instrumental in conceiving and building creative IT solutions to help solve business challengers, first at Motorola and then at bioMerieux and now at Moderna Therapeutics. His expertise is in visioning, strategizing and implementing innovative programs to update and streamline the digital landscapes. He is known for his ability to transform a company's Information flow, and ultimately improving the product and the company's processes through digitization.

Mr. Damiani possesses a Master of Science degree in Information Systems Architecture from the University of Toulouse in France, and an international Executive MBA through TRIUM, an alliance of three of the world's top universities: the London School of Economics, New York University Stern Business School and the HEC School of Management in Paris.

Download the detailed event brochure

Get the agenda and speaker line-up to your inbox – Download the brochure